Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study

Fig. 3

The resistance gene spectrum of EGFR mutation in NSCLC patients. A The gene change frequency after progression to EGFR-TKIs in NSCLC patients. B The main resistance mechanism in PG. C The gene change in SCLC transformation subgroup. D The main resistance mechanism in CG. E The resistance mechanism after failure to 1st or 2nd generation EGFR-TKIs. F The resistance mechanism to the 3rd generation EGFR-TKIs. G The co-occurring resistance genes in the research. PG, Personalized group; CG, Chemotherapy group

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us